Aurealistherapeutics
Founded 2015 · 17 employees on LinkedIn · 1 known investors
Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.
Founders & leadership
Aurealistherapeutics was founded in 2015 by Juha Yrjänheikki.
Investors · 1
Frequently asked questions
- What does Aurealistherapeutics do?
- Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.
- Who founded Aurealistherapeutics?
- Aurealistherapeutics was founded by Juha Yrjänheikki in 2015.
- Who are Aurealistherapeutics's investors?
- Aurealistherapeutics's investors include Innovestor Ventures.